文献速递细菌感染、耐药与抗菌药物

无并发症淋病治疗药物的药代动力学/药效学考量:挑战与机遇

Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea-challenges and opportunities.
PubMed 文献 · Clin Microbiol Infect · 2020-08-13

本文综述淋球菌特异性PK/PD原理及剂量探索策略,梳理体外与体内模型在药物暴露与临床结局关联中的进展。全球专家专题研讨会指出,预测新药临床结局需要经验证的非临床PK/PD模型,以降低III期失败和耐药风险。

要点

  • 淋球菌耐药上升亟需新抗生素,近期两种新药非劣效于头孢曲松联合阿奇霉素失败
  • 经验证的非临床PK/PD模型是确定理想药物与剂量、降低III期失败风险的关键
  • 体外与体内模型适配淋病的进展有助于新药开发和减少耐药出现

核心结论

  • 确定治疗无并发症泌尿生殖道和咽部淋病的理想抗菌药物与剂量,需要适当且经验证的非临床PK/PD模型。
  • 近期两种新抗生素与当前一线头孢曲松联合阿奇霉素相比未显示非劣效,凸显改进临床前预测工具的需要。
  • 适配淋病的体外与体内模型进展可降低III期临床开发失败风险和耐药出现风险。

研究设计与样本

  • 文献综述结合全球专家在专题研讨会上的讨论。

主要发现

  • 淋球菌多重耐药率上升,迫切需要新抗生素治疗淋病。
  • 该领域数十年药物开发低迷,近期两种新药非劣效性研究失败。
  • 综述了淋球菌特异性PK/PD原理及将药物暴露与临床结局关联的新体外和体内模型。

临床怎么用

  • 开发淋病新药时应采用经验证的非临床PK/PD模型进行剂量探索,以预测临床结局。

局限性

  • 本文为文献综述与专家讨论,未报告具体研究样本量、阈值或统计数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing multidrug resistance rates in Neisseria gonorrhoeae have raised concerns and an urgent call for new antibiotics for treatment of gonorrhoea. Several decades of subdued drug development in this field and the recent failures of two new antibiotics to show non-inferiority compared with the current first-line antibiotics ceftriaxone plus azithromycin highlight the need for improved preclinical tools to predict clinical outcome of new drugs in the development process. OBJECTIVES: To summarize current pharmacokinetic/pharmacodynamic (PK/PD) knowledge and dose-finding strategies for antibiotics against gonorrhoea. SOURCES: Literature review of published papers and discussions by global experts at a special workshop on this topic. CONTENT: We review current knowledge of gonococcal specific PK/PD principles and provide an update on new in vitro and in vivo models to correlate drug exposure with clinical outcome, and identify challenges and gaps in gonococcal therapeutic research. IMPLICATIONS: Identifying the ideal antimicrobial agent and dose for treating uncomplicated urogenital and pharyngeal gonococcal disease requires appropriate validated non-clinical PK/PD models. Recent advances in adapting in vitro and in vivo models for use in gonorrhoea are an important step for enabling the development of new drugs with reduced risk of failure in Phase 3 clinical development and diminish the risk of emergence of resistance.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Theuretzbacher U, Barbee L, Connolly K, et al. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea-challenges and opportunities. Clin Microbiol Infect. 2020. PMID: 32798687. doi:10.1016/j.cmi.2020.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。